J&J Covid-19 Vaccine Trial Moves Into Late Stage
Mohammad Ali (@ChaudhryMAli88) Published September 23, 2020 | 09:17 PM
Johnson & Johnson said Wednesday it was entering the final Phase 3 stage of its Covid-19 vaccine clinical trial following positive results in earlier stages
Washington, (APP - UrduPoint / Pakistan Point News - 23rd Sep, 2020 ) :Johnson & Johnson said Wednesday it was entering the final Phase 3 stage of its Covid-19 vaccine clinical trial following positive results in earlier stages.
The trial will seek to enroll up to 60,000 volunteers across more than 200 sites in the US and around the world, the company and the US National Institutes for Health (NIH), which is providing funding, said.
With the move, J&J becomes the tenth maker globally to conduct a Phase 3 trial against Covid-19, and the fourth in the US.
The company, which is developing the vaccine on a not-for-profit basis through its subsidiary Janssen, said it anticipated the drug would be ready for emergency approval by early 2021 if proven safe and effective.
"As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same -- leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic," said Alex Gorsky, the company's chairman and CEO.
Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases, added: "Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified." "This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry and academia." The US has given J&J about $1.45 billion in funding under Operation Warp Speed.
The vaccine is based on a single dose of a cold-causing adenovirus, modified so that it can no longer replicate, combined with a part of the new coronavirus called the spike protein that it uses to invade human cells.
J&J used the same technology in its Ebola vaccine which received marketing approval from the European Commission in July.
The company said it was poised to imminently publish the results from an earlier stage of the trial on a medical preprint site.
Related Topics
Recent Stories
SC orders end of encroachments in Karachi
Nazish Jahangir denies viral screenshots, calls them fake
Govt likely to hike electricity price once again
Bismah Maroof announces immediate retirement from international cricket
Malala expresses unwavering support for Gaza people
Selection committee dissolved over Pakistan women cricket team's poor performanc ..
Punjab CM Maryam Nawaz in police uniform at Chung police center
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 25 April 2024
Today Gold Rate in Pakistan 25 April 2024
Mired in crisis, Boeing reports another loss
Session Awarding Ceremony 2024 held at Cadet College Muzaffarabad
Austrian ski great Hirscher to make comeback under Dutch flag
More Stories From World
-
Portugal marks 50 years of democracy with far right on rise
19 minutes ago -
Pakistan envoy visits TomatoWorld in Netherlands
29 minutes ago -
Chinese defense minister to attend SCO meeting in Kazakhstan
29 minutes ago -
China, Pakistan should engage in greater counter-terrorism cooperation to combat hostile forces: Khu ..
29 minutes ago -
Scottish leader scraps coalition deal with Greens
29 minutes ago -
Macron, in key speech, warns that Europe 'is mortal'
29 minutes ago
-
China continues to battle flood in Pearl River basin
39 minutes ago -
Death toll from Tanzania's flash floods rises to 155: PM
49 minutes ago -
Iron ore futures close higher
59 minutes ago -
Two runaway army horses in 'serious condition': UK minister
59 minutes ago -
Myanmar's health ministry issues heat advisory amid soaring temperature
1 hour ago -
Russian oil production facility in Siberia catches fire
1 hour ago